Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes

Biomarkers

Volumn 21, Issue 2, 2016, Pages 164-167

  Shoji, M ^a,b   Kobayashi, K ^a,b   Takemoto, M ^a,b   Sato, Y ^b   Yokote, K ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biomarker; diabetic nephropathy; podocyte; urinary podocalyxin

Indexed keywords

ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PODOCALYXIN; BIOLOGICAL MARKER; SIALOGLYCOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; ALBUMINURIA; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE COURSE; EARLY DIAGNOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; URINE;

AGED; ALBUMINURIA; BIOMARKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SIALOGLYCOPROTEINS;

EID: 84949236070     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1118551     Document Type: Article

References (13)

1. Asao R, Asanuma K, Kodama F, et al. (2012). Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol 7:1385-93.
2. Betsholtz C, He L, Takemoto M, et al. (2007). The glomerular transcriptome and proteome. Nephron Exp Nephrol 106:e32-6.
3. Hara M, Yamagata K, Tomino Y. (2012). Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: Establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 55:2913-19.
4. Hara M, Yanagihara T, Hirayama Y, et al. (2010). Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum Pathol 41:1265-75.
5. Jha V, Garcia-Garcia G, Iseki K, et al. (2013). Chronic kidney disease: Global dimension and perspectives. Lancet 382:260-72.
6. Kobayashi K, Yokoh H, Sato Y, et al. (2014). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alphaglucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): A multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes Metab 16:761-5.
7. Lin H, Ye S, Xu J, et al. (2015). The alpha-lipoic acid decreases urinary podocalyxin excretion in type 2 diabetics by inhibiting oxidative stress in vivo. J Diabetes Complications 29:64-7.
8. Palacios De Franco Y, Velazquez K, Segovia N, et al. (2015). Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 12:115-24.
9. Sakamoto K, Kuno K, Takemoto M, et al. (2015). Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuries. J Diabetes Res 2015:727152
10. Suwanpen C, Nouanthong P, Jaruvongvanich V, et al. (2015). Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity. J Nephrol [Epub ahead of print]. DOI: 10.1007/s40620-015- 0199-8
11. Takemoto M, Ishikawa T, Onishi S, et al. (2013). Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia. Diabetes Res Clin Pract 100:e26-9.
12. Wiggins RC. (2007). The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 71:1205-14.
13. Yokoh H, Kobayashi K, Sato Y, et al. (2015). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alphaglucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig 6:182-91.